Lake Street analyst Thomas Flaten maintained a Buy rating on Evaxion Biotech (EVAX – Research Report) today and set a price target of $6.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback